Michael Makris: How Haemophilia Care Is Delivered in China
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, reposted from RPTH Journal on LinkedIn:
”If you would like to know how haemophilia care is delivered in China then have a look at this paper.”
Quoting RPTH Journal‘s post about a recent article by Yun Wang et al, adding:
”Inherited bleeding disorders in China: a rapidly evolving therapeutic and healthcare landscape
With over 1.4 billion people, China faces a growing demand for the diagnosis and treatment of inherited bleeding disorders (IBDs), particularly haemophilia.
A new review in RPTH Journal takes stock of the remarkable progress made in recent years and the road ahead.
Key highlights:
- China is rapidly expanding its domestic manufacturing capacity for IBD therapeutics, from basic replacement therapies to advanced treatments including gene therapy
- A tiered healthcare system for haemophilia is being developed to optimise resource allocation and standardise care across both rural and urban areas
- A diverse pipeline of investigational domestic novel drugs is under active development
- The goal: more efficient, cost-effective, and accessible care for patients nationwide
This review offers a comprehensive overview of where China stands today, and where it is headed, in the management of inherited bleeding disorders.
The combination of domestic drug innovation and an evolving healthcare delivery system could significantly improve outcomes and quality of life for patients across the country.”
Title: The therapeutic landscape of inherited bleeding disorders in China
Authors: Yun Wang, Feng Xue, Man-Chiu Poon, Renchi Yang
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 4, 2026, 05:38Faizan Khan: Why Common Exposures Matter in VTE Risk
-
Sep 4, 2026, 04:56Marwa Mostafa: Microcytosis Is Not Always Iron Deficiency
-
Sep 4, 2026, 03:18Mukesh Kumar Maurya: Beyond ‘aPL Thrombosis’ – A Modern Approach to APS
-
Sep 4, 2026, 02:44Ahmed Kotb: Emergency Management of Critical Bleeding in ITP
-
Sep 4, 2026, 02:30Mario Jimenez: KDIGO 2026 – A More Proactive Approach to IV Iron in Hemodialysis
-
Sep 4, 2026, 02:18Edgardo Alania: Edoxaban in Intracranial Haemorrhage Survivors with AF
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community